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FNC-B4 neuroblasts that express both neuronal and olfactory
markers have been established and cloned. These cells ex-
pressGnRHandboth theendothelin-1 (ET-1) geneandprotein
and respond in a migratory manner to GnRH in a dose-de-
pendent manner. Previous research has shown that FNC-B4
cells produce and respond to ET-1 by regulating the secretion
of GnRH through endothelin type A receptors and by stimu-
lating their proliferation through endothelin type B (ETB)
receptors. In this study, we found that FNC-B4 cells are able
to migrate in response to ET-1 through the involvement of
ETB receptors. Combined immunohistochemical and bio-
chemical analyses showed that ET-1 triggered actin cytoskel-
etal remodeling and a dose-dependent increase in migration
(up to 6-fold).Whereas theETB receptor antagonist (B-BQ788)
blunted theET-1-induced effects, theETAreceptor antagonist
(A-BQ123) did not. Moreover, we observed that FNC-B4 cells
were independently and selectively stimulated by ET-1 and
GnRH. We suggest that ET-1, through ETB receptor activa-
tion, may be required to maintain an adequate proliferative
stem cell pool in the developing olfactory epithelium and the
subsequent commitment to GnRH neuronal migratory pat-
tern. The coordinate interaction between ET receptors and
GnRH receptor participates in the fully expressed GnRH-se-
creting neuron phenotype. (Endocrinology 146: 4321–4330,
2005)
HOW CELLS INITIATE, maintain, and stop their mi-gration remains a fascinating problem in many de-
velopmental systems. Although the GnRH-secreting neu-
rons are located postnatally within the forebrain, during
embryogenesis, they arise from the olfactory placode and
then migrate into the hypothalamus (1, 2). Proper spatio-
temporal expression of transcription factors plays a crucial
role in these processes, both in guiding GnRH-secreting neu-
rons during their migration and in orchestrating their sub-
sequent differentiation (3). Although the endothelin (ET)
family was initially characterized as potent vasoactive pep-
tides, a variety of other biological functions were subse-
quently discovered, such as stimulation of hormone release
and regulation of central nervous system activity (4–7). In
particular, ET immunoreactivity (8) and ET receptors (9) are
present in median eminence and arcuate nucleus, in which
GnRH neurons are mostly concentrated. Interestingly, ET
peptides stimulate GnRH release from hypothalamic ex-
plants (10), fetal rat hypothalamic neurons (11), and fetal
human olfactory cells (12).
Recent gene-inactivation studies of the components of the
ET pathway have revealed some other unexpected roles of
these peptides, especially during mammalian development.
Mice deficient in endothelin-1 (ET-1), endothelin type A
(ETA) receptor, and endothelin-converting enzyme-1 have
defects in the development of subsets of cephalic and cardiac
neural crest derivatives, including branchial arch-derived
craniofacial tissues, and great vessel and cardiac outflow
structures (13–16). Mice deficient in endothelin-3 (ET-3) or
endothelin type B (ETB) receptor show spotted coat color and
aganglionic megacolon due to defects in the development of
neural crest-derived melanocytes and enteric neurons, re-
spectively (17, 18). In humans, multigenic Hirschsprung’s
disease, or congenital aganglionosis of the distal gut, is
caused by a failure of the neural crest cells to form ganglia
in the distal part of the gut. This disease is characterized by
pigmentation defects, deafness, and megacolon (19–21).
New insights into the pathogenesis and the molecular basis
of this abnormality in humans have been gained from the
identification of certain critical genes, such as ET-3 and the
ETB receptor in mice. These genes play a role in the devel-
opment of the peripheral nervous system and in that of the
connective tissue in the face, neck, and heart (22, 23). Recent
research has demonstrated that genetic interactions between
mutations in receptor for glial-derived neurotrophic factors
(RET, receptor protein tyrosine kinase) and the ETB receptor
is one of the underlying mechanisms for this complex dis-
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order (24). Furthermore, the interaction between the RET and
ETB receptor loci in humans and mice regulates enteric ner-
vous systemdevelopment in the distal colon. It also regulates
the coordinated and balanced interaction between RET and
ETB receptor signaling pathways and controls the develop-
ment of the mammalian enteric nervous system throughout
the intestine (25). Recently, it has been demonstrated that
temporally distinct requirements for ETB receptor occur in
the proliferation and migration of gut neural crest stem cells
(26). In a previous research, we showed that GnRH-secreting
neurons, FNC-B4 cells, produce and respond to ET-1 and that
this peptide regulates GnRH-secretion or cell proliferation,
depending on which subtype of the ET receptor is activated
(12). Moreover, GnRH acts in an autocrine/paracrine pattern
to promotemigration of FNC-B4 neuroblasts (27). The aim of
this study was to elucidate the role played by ET-1 in the
migratory pattern of GnRH-secreting neurons. FNC-B4 cells
dose dependently migrated in response to ET-1 through the
involvement of ETB receptor. We also report that GnRH and
ET-1 act in a biologically independent and selective manner,
and their recruitment is able to elicit a functional crosstalk
during migration.
Materials and Methods
Cell cultures
The primary humanGnRH-secreting neuronal cell line, FNC-B4 cells,
has been established, cloned, and propagated in vitro from the fetal
olfactory system and cryogenically preserved. FNC-B4 cells have been
phenotypically, biochemically, and functionally characterized (12, 27–
31). These cells grow as a monolayer, are nontumorigenic, and have a
normal human karyotype. The immortalized GnRH-expressing neuro-
nal cell line, GN11 cells, was used in some experiments (generously
provided by S. Radovick, University of Chicago, Chicago, IL). GN11
neuronal cells have been isolated from olfactory bulb tumors of migra-
tion-arrested GnRH neurons (32). The human neuroblastoma SH-SY5Y
cell line, a clonal derivative fromprimary tumor of neural crest cells, was
used in some experiments [these cells are commercially available from
American Type Culture Collection (Manassas, VA) and LGC Promo-
chem (Teddington, UK)]. This cell line has been previously established
and extensively characterized both phenotypically and biochemically
(33–35). The primary humanGnRH-secreting neuronal cell line FNC-B4,
the immortalized GnRH-expressing neuronal cell line GN11, and the
SH-SY5Y cell line show different biochemical and functional neuronal
features that mimic some of the biochemical and functional heteroge-
neity that is characteristic of the developing nervous system. These cell
types were cultured at 37 C in 5% CO2 atmosphere in Coon’s modified
F-12 medium (Irvine Scientific, Santa Ana, CA), supplemented with 4.5
g/l glucose, 10% fetal bovine serum (Eurobio, Les Ulis, France), and
antibiotic/antimycotic solution (penicillin, 100 IU/ml; streptomycin,
100 g/ml).
Chemicals
[125I]GnRH (2200 Ci/mmol) was obtained from PerkinElmer Life
Science Products (Milan, Italy). [125I]ET-1 (2000 Ci/mmol) was pur-
chased from Amersham Biosciences (Amity PG, Milan, Italy). A GnRH
RIA kit was obtained from Buhlmann Laboratories (Allschwil, Switzer-
land). Unlabeled ET-1 and the ETA-selective antagonist A-BQ123 were
obtained from NovaBiochem (Laufelfingen, Switzerland). The ETB-se-
lective agonist IRL-1620 and antagonist B-BQ788 were purchased from
Alexis (Laufelfingen, Switzerland). The polyclonal antibodies to ET-1
(RAS 6901) were purchased from Peninsula Laboratories (San Carlos,
CA). Synthetic GnRHwas obtained from Incstar (Stillwater,MN). GnRH
agonist buserelin (d-tert-butyl-Ser6-des-Gly10-Pro9-ethylamide-GnRH)
was purchased from Sigma (St. Louis, MO). GnRH antagonist cetrorelix
[Ac-d-Nal (2)1, d-Phe (4Cl)2, d-Pal (3)3, d-Cit6, d-Ala10] was purchased
from ASTA Medica (Frankfurt, Germany). The rabbit polyclonal anti-
bodies to the ETA and ETB receptors were provided by Assay Design
(Ann Arbor, MI) and were used at 1:100 concentration; the antigoat
polyclonal neuron-specific enolase (NSE) antibody (1:100 dilution) sc-
7455 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
3,4,3,4, Tetra-aminodiphenilhydrochloride (diaminobenzidine) was
obtained from BDH Chemicals (Poole, UK). Streptavidin-biotin perox-
idase complex kits were obtained from Dako (Carpinteria, CA). Other
reagents were obtained at the highest grade available from commercial
sources or from Sigma.
Isolation of RNA and cDNA synthesis
Total RNA was extracted from cells using RNAase mini kit from
Qiagen (Valencia, CA) according to the instructions of themanufacturer.
RNA concentration and quality were measured by spectrophotometric
analysis at 260 and 280 nm. RNA integrity was assessed by electro-
phoresis in agarose gel. Total RNA (400 ng) was reverse transcribed to
cDNA in a final volume of 80 l using TaqMan Reverse Transcription
kit (Applied Biosystems, Foster City, CA) at the following conditions: 10
min at 25 C, 30 min at 48 C, and 5 min at 95 C.
Real-time quantitative RT-PCR
The mRNA quantitative analysis was performed according to the
fluorescent TaqMan methodology, as published previously (36). PCR
primers and probe for mRNA quantitation of ET-1 receptors (ETA and
ETB) were purchased as an assay-on-demand (AOD) gene expression
product fromApplied Biosystems. The glyceraldehyde-3-phosphate de-
hydrogenase gene was chosen as the reference gene, and the corre-
sponding AOD product was provided by Applied Biosystems. The PCR
mixture (25 l final volume) consisted of 1 final concentration of AOD
mix, 1 final concentration of Universal PCR Master mix (Applied
Biosystems), and 25 ng cDNA. Amplification and detection were per-
formedwith an ABI Prism 7700 Sequence Detection System (version 1.7)
(Applied Biosystems) with the following thermal cycler conditions: 2
min at 50 C, 10 min at 95 C, and 40 cycles at 95 C for 30 sec and 60 C
for 1 min. Eachmeasurement was performed in duplicate. mRNA quan-
titation was based on the comparative CT method, according to the
instructions of the manufacturer, in which CT represents the cycle num-
ber at which the fluorescent signal, associated with an exponential
increase in PCR products, crossed a given threshold. The maximum
change in CT values of the sample (CT sample) was determined by
subtracting the average of duplicate CT values of the reference gene from
the average of the duplicate CT values of the target gene. Human um-
bilical vascular endothelial cells (HUVEC) (37), classically considered
positive targets for ETB ligands, together with the SH-SY5Y cell line,
were used as controls.
Measurement of intracellular calcium concentration
Digital video imaging of the intracellular-free calcium concentration
([Ca2]i) in individual human FNC-B4 cells was performed as described
previously (27). Human neurons were grown to subconfluence in com-
plete culture medium on round glass coverslips (25-mm diameter,
0.2-mm thick) for 72 h and then incubated for 48 h in serum-freemedium
(SFM) at 37 C. Cells were then loaded with 10 mol/l fura 2-AM and
15% Pluronic F-127 for 30 min at 22 C. [Ca2]i was measured in fura
2-loaded cells in HEPES-NaHCO3 buffer containing the following (in
mmol/l): 140 NaCl, 3 KCl, 0.5 NaH2PO4, 12 NaHCO3, 1.2 MgCl2, 1.0
CaCl2, 10 HEPES, and 10 glucose (pH 7.4). Ratio images (340/380 nm)
were collected every 3 sec, and calibration curves were obtained for each
cell preparation. ET-1, ETA, and ETB receptor antagonists (A-BQ123 and
B-BQ788), GnRH and/or its analog (buserelin), and GnRH antagonist
(cetrorelix) (from 0.1 m to 1 nm) were directly added to the perfusion
chamber immediately after recording the [Ca2]i basal value. In parallel
experiments, cells were preincubated with 0.1 m ETB receptor antag-
onist for 10 min before addition of ET-1. These experiments were done
in triplicate.
Immunocytochemical procedures and confocal
laser microscopy
FNC-B4 cells were cultured on glass coverslips in SFM for 18 h and
then left untreated or incubated with ET-1. Cells were then fixed with
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3.7% paraformaldehyde (pH 7.4) for 10 min and then permeabilized for
10 min with PBS (Ca2/Mg2-free), containing 0.1% Triton X-100. Im-
munostaining was performed as described previously (12, 23), using
polyclonal antibodies to ETA and ETB receptor (1:50), followed by
streptavidin-biotin peroxidase complex (LSABkit; Dako). The specificity
of the anti-ETA and ETB receptor antibodies was controlled by preab-
sorption of the primary antibodies with a membrane preparation from
human fetal penile smoothmuscle cells (hfPSMC), particularly enriched
in the respective receptors, as detected by binding experiments (38),
according to a previously described method (39). Briefly, ETA and ETB
receptor antibodies (working dilution) were incubated with 1 mg/ml
hfPSMC membranes in 50 mm Tris HCl buffer, or with buffer only,
overnight at 4 C. After an additional 60-min incubation with 4% poly-
ethylene glycol, the unbound antibodies were separated by rapid cen-
trifugation and used for immunohistochemistry. Filamentous actin (F-
actin) was stained with rhodamine phalloidin (1:50; Molecular Probes,
Eugene, OR) in the permeabilization solution for 45 min at room tem-
perature. Cells were viewed with a laser scanner confocal microscope
(MRC 600; Bio-Rad, Hercules, CA), equipped with a Nikon (Tokyo,
Japan) diaphot inverted microscope or with a Nikon Microphot-FX
microscope. The percentages shown in Figure 3 concerning various
morphologies of actin-based cell deformations (i.e. percentage of cells
showing at least two of the following morphological features: actin
patches, filopodia, lamellipodia, and membrane ruffles) were obtained
by counting the number of activated cells over the total number of
stained cells from three different experiments (at least three slides for
each experiment and five fields from each slide).
GnRH and ET-1 RIA
Immunoreactive GnRH was extracted from conditioned media of
FNC-B4 cells with chilled absolute ethanol (20 C), evaporated to dryness,
and subjected to RIA using a commercial kit (Buhlmann Laboratories), as
described previously (31). Immunoreactive ET-1 was extracted from con-
ditioned media of FNC-B4 cells using Sep-Pak C18 cartridges (Millipore,
Milford, MA), as described previously (12). The specific RIA for ET-1 was
performed in 0.1mPBS [0.1%TritonX-100, 0.1%BSA, and 0.01%NaN3 (pH
7.4)] by a two-step incubation procedure. Samples and standards (0.1 ml)
were incubated at 4 C overnight with the respective antiserum (ET-1:
RAS6901, 1:20,000, 0.1 ml) and further incubated with the respective tracer
(0.1 ml, 10 pm) at 4 C overnight. Bound/free separation was performed by
a second antibody/polyethylene glycol procedure.
SDS-PAGE, Western blot analysis, and immunoblotting
FNC-B4 cells, grown to confluence, were scraped into PBS (Ca2/
Mg2-free), centrifuged, and resuspended in lysis buffer [20 mm Tris-
HCl, 150 mm NaCl, 0.25% Nonidet P-40, 1 mm Na3VO4, 1 mm phenyl-
FIG. 1. A, Quantitative gene expression of
ET-1 receptors in FNC-B4 cells and SH-SY5Y.
The top shows the quantitative detection of
mRNA (RT-PCR) for ETA and ETB receptors
in FNC-B4 and SH-SY5Y neural cells. Expres-
sion of the same genes in HUVEC was also
shown for comparison. ETB transcripts were
definitively higher in GnRH-secreting neu-
rons and neuroblastoma cells than in endo-
thelial cells, used as positive control. Data
(mean  SD; n  3) are expressed in arbitrary
units, calculated according to the comparative
CT method and normalized to the glyceralde-
hyde-3-phosphate dehydrogenase, chosen as
reference gene. The bottom shows the expres-
sion of ETA and ETB proteins in the same
neuronal cells, as determined by Western blot
analysis. Specific bands, of the expected sizes,
were detected using rabbit polyclonal antibod-
ies against ETA (left) and ETB (right) recep-
tors. B, Immunohistochemistry for ET-1 re-
ceptors in FNC-B4 neurons. The intracellular
localization of ETA (panel a) and ETB (panel
b) receptors in FNC-B4 was revealed by the
same antibodies as in A (bottom). Note the
positivity for ETA and ETB receptors in the
perinuclear cytoplasmic compartment, with a
fading localization within the tiny cytoplasmic
protrusions (see arrows). Positive staining for
both ETA (panel c) and ETB (panel d) recep-
tors disappeared after preabsorbing the two
antibodies with amembrane preparation from
hfPSMC, enriched in the respective receptors.
Scale bar, 0.3 m.
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methylsulfonylfluoride, 1 mm EGTA (pH 7.4)]. Protein concentration
was measured using a Coomassie Bio-Rad protein assay kit. Aliquots
containing 30 g of proteins were diluted in 2 reducing Laemmli’s
sample buffer [62.5 mm Tris (pH 6.8), 10% glycerol, 20% SDS, 2.5%
pyronin, and 100 mm dithiothreitol] and loaded onto 10% SDS-PAGE.
After SDS-PAGE, proteinswere transferred to nitrocellulosemembranes
(Immobilon-P transfer membranes, polyvinylidene difluoride; Milli-
pore). Membraneswere blocked overnight at 4 C in 5% BSA-TTBS buffer
(0.1% Tween 20, 20 mm Tris-HCl, and 150 mm NaCl), washed in TTBS,
and incubated for 2 h with anti-actin primary antibody (1:1000 dilution),
followed by peroxidase-conjugated secondary IgG (1:3000). Finally, the
reacted proteins were revealed by enhanced chemiluminescence system
(ECL; Roche Diagnostics, Basel, Switzerland). For reprobing with dif-
ferent antibodies, the nitrocellulose membranes were washed for 30 min
at 50 C in stripping buffer [10 mm Tris (pH 6.8), 2% SDS, 100 mm
b-mercaptoethanol] and reprobed with antigoat NSE antibody (1:100
dilution; sc-7455; Santa Cruz Biotechnology).
Chemotactic assay
Cell migration was performed as described previously (27). Briefly,
modified Boyden chambers (Nuclepore, Pleasanton, CA), each equipped
with a 13-mmdiameter and a 5- or 8-mporosity polyvinylpyrrolidone-
free polycarbonate filter were used. The filters were coated with 20
g/ml human type I collagen or 10 g/ml fibronectin (Collaborative
Biomedical Products, Bedford, MA) for 30 min at 37 C. Confluent
FNC-B4 cells, GN11 cells, and SH-SY5Y cells were incubated in SFM for
24 h (control conditions). After mild trypsinization with 0.05% trypsin-
EDTA, in 210-l aliquots, each of which corresponding to 4  104
cells/Boyden chamber, the cells were added to the top wells and incu-
bated at 37 C in 5% CO2 for 6 h. Increasing concentrations of ET-1, or
IRL-1620, in the presence or absence of ETA and/or ETB receptor an-
tagonists (A-BQ123 or B-BQ788; 107 m concentration), and GnRH or
buserelin, in the presence or absence of cetrorelix (107m concentration),
were added to the bottom chambers. Both ET-1 and GnRH were incu-
bated in the presence of cetrorelix or A-BQ123/B-BQ788, respectively.
After incubation, the migrated cells were fixed in 96% methanol and
stained with Diff Quick solution (Biomap, Milan, Italy) or Harris’ he-
matoxylin solution. Chemotaxis was quantitated by randomly counting
six chosen fields per filter, and results were expressed as the number of
cells per high-power field (HPF).
Statistical analysis
Data are expressed as the mean sd. An one-way ANOVA followed
by post hoc test (Bonferroni’s correction for multiple comparisons) was
FIG. 2. Measurement of intracellular calcium concen-
tration. Digital video imaging of [Ca2]i in individual
human FNC-B4 cells. ET-1, BQ123 and BQ788, GnRH
or buserelin, and cetrorelix were added directly to the
perfusion chamber immediately after recording the
[Ca2]i basal value. In parallel experiments, cells were
preincubatedwith 0.1METBreceptor antagonist for 10
min before the addition of ET-1 (black trace). BQ123was
able to almost blunt (70  2%) [Ca2]i transients (white
circles), whereas BQ788 abolished only 30 3% of cases
of ET-1-induced [Ca2]i increases (black circles). Con-
temporary exposure to both antagonists blunted the ef-
fects of ET-1 (gray triangles).
FIG. 3. Effects of ETB receptor activation in FNC-B4
neurons on F-actin. FNC-B4 cells were cultured on glass
coverslips in SFM for 24 h and then left untreated (CTL)
or incubated for 18 h with ET-1 (107 M). F-actin, after
fixation, was visualized with rhodamine phalloidin (1:
50) in the permeabilization solution for 45 min at room
temperature. Cells were viewed with a laser scanner
confocal microscope. A typical patter of expression of
F-actin in unstimulated FNC-B4 cells is shown (CTL).
ET-1 (100 nM) exerted striking activation of cell mor-
phology, togetherwith actin stress fiber network, toward
a spindle-like shape, with actin-based cell deformation
and the presence of actin patches (thin arrow), together
with the appearance of lamellipodia (arrowhead) and
filopodia (thick arrow) on the edge of cell membranes
(ET-1). Simultaneous incubationwithET-1 (100 nM) and
BQ123 (100 nM) induced similar actin-based cytoskel-
etal modifications than ET-1 alone (ET-1BQ123) (see
arrows); vice versa, coincubation of ET-1 (100 nM) and
BQ788 (100 nM) did not induce morphological changes
different from controls (ET-1BQ788).Scale bar, 0.15m.
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performed. The level of P 0.05 was accepted as statistically significant.
Comparisons of percentages were analyzed statistically after conversion
through arc-sine transformation from the binomial to the normal dis-
tribution. The computer program ALLFIT was used for the analysis of
the sigmoidal dose-response curves (40).
Results
ETB receptor expression in human FNC-B4 cells
Figure 1A (top) shows ETA and ETB mRNA expression
(quantitative RT-PCR) in neuronal compared with endothe-
lial cells, taken as positive controls. Both GnRH-secreting
neurons and neuroblastoma cells express, respectively, a 4-
and 15-fold higher concentration of ETB transcripts than
HUVEC, classically considered positive targets for ETB li-
gands (37). Western blot analysis with polyclonal anti-ETA
and anti-ETB antibodies (Fig. 1A, bottom) shows specific
bands for both receptors, at the expected molecular weight,
in both FNC-B4 or SH-SY5Y cells. The intracellular immu-
nodistribution of ETA and ETB in FNC-B4 cells is shown in
Fig. 1B. Note the positivity for both receptors in the perinu-
clear cytoplasmic compartment, with a fading localization
within the tiny cytoplasmic protrusions (Fig. 1B).
Intracellular signaling activated by ET-1 in FNC-B4 cells
A typical experiment on ET-1-induced intracellular cal-
ciummobilization in fura 2-loaded FNC-B4 cells is shown in
Figure 2. ET-1 (107 m) induced in control cells a transient
and sustained activation of calcium waves. This stimulation
was partially blunted by the ETB antagonist B-BQ788, al-
though it was substantially inhibited by the ETA antagonist
A-BQ123. Quantitative analysis of multiple results (data not
shown) indicated that A-BQ123 inhibits 70  2% and B-
BQ788 inhibits 30  3% of the ET-1-induced calcium mobi-
lization. Only the simultaneous presence of both antagonists
almost abolished ET-1-stimulated calcium transients (Fig. 2).
These results suggest that both receptors are involved in
mobilizing intracellular calcium in FNC-B4 cells.
Biological effects of ETB receptor activation in
FNC-B4 neurons
Unstimulated FNC-B4 cells showed an intense actin stress
fiber network, as detected by F-actin conjugated with rho-
damine phalloidin (Fig. 3,CTL). In this assay, a small fraction
(10  2%; n  3) of unstimulated cells displayed actin cy-
toskeletal remodeling. After 18 h of exposure to ET-1 (107
m) (Fig. 3, ET-1), we noticed a significant increase (68  2%;
n 3; P 0.0005; ET-1 vs. control) in various actin-based cell
deformations, i.e. actin patches (thin arrow), filopodia (thick
arrow), lamellipodia (arrowhead), and membrane ruffles. In
addition, we documented an ET-1-induced development of
broad lamellae, prominent lamellipodia, numerous mem-
brane ruffles, and microspikes, compatible with a motile
phenotype. A-BQ123 (107 m) was ineffective in antagoniz-
ing ET-1 effects (65  3%; n  3; P  0.005) (Fig. 3, ET-
1BQ123), whereas B-BQ788 (107 m) was able to elicit ET-
1-induced phenotype modifications [15 3%; n 3; P value
was not significant (ns)] (Fig. 3, ET-1BQ788). These ET-1-
induced cytoskeletal rearrangementswere further confirmed
by Western blot analysis using actin antiserum recognizing
actin protein at the expectedmolecularweight (Fig. 4A). ET-1
induced a significant increase (P 0.023) in actin expression,
not reverted (P 0.05) by A-BQ123 but reverted by B-BQ788
(P value was ns) (Fig. 4B). To assess equal protein loading,
nitrocellulose membranes were stripped and reprobed with
anti-NSE (we thus observed no significant modifications ei-
ther after ET-1 exposure or inhibitors’ stimulation in the
presence of ET-1) (Fig. 4C). Because ET-1 induced a motile
phenotype in FNC-B4 cells, we studied whether or not ET-1
induced cell migration by using the chemotactic Boyden
chamber technique (cell migration toward regions at higher
concentration of chemotactic factors). FNC-B4 neuronal cells
responded in a migratory manner to ET-1 (Fig. 5A). In par-
ticular, FNC-B4 responded to SFM with a time-dependent
increase in spontaneous random migration (7  1.4 cells per
HPF after 6 h of incubation; n  30). ET-1 stimulated a 4- to
6-fold increase in this migratory pattern in the FNC-B4 cells
in a dose-dependent manner (from 109 to 107 m) (n  12;
*, P 0.0005 vs. SFM). Whereas the ETA receptor antagonist
A-BQ123 was ineffective to completely counteract ET-1-in-
FIG. 4. Effects of ETB receptor activation on actin expression in
FNC-B4 neurons. FNC-B4 cells were cultured in SFM for 24 h, in-
cubated for 18 h with ET-1 (107 M), and then subjected to Western
blot analysis of actin (A). A single protein band, migrating at the
expected molecular weight, is indicated by the arrowhead. ET-1 stim-
ulated actin expression (*, P  0.05 vs. control). This enhanced ex-
pression was reverted by BQ788 but not by BQ123 (*, P  0.05 vs.
control). Quantification of actin increase is reported in B (percentage
of increase in actin expression over the control value, taken as 100%).
Experiments were done in triplicate. *, P 0.05. Nitrocellulose mem-
branes were stripped and reprobed with anti-NSE to assess equal
protein loading (C). No modification was observed in NSE expression
among lanes (data not shown). CTL, Control.
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duced migratory pattern (n  12; *, P  0.0005 vs. SFM), the
ETB receptor antagonist B-BQ788was able to blunt this effect
(P value was ns). The data suggest the main involvement of
ETB receptor in the migration of FNC-B4. This was further
confirmed by the incubation with an ETB receptor-selective
agonist (IRL-1620, 107 m) (n  12; *, P  0.0005 vs. SFM). A
representative pattern of migrating cells on the Boyden
chamber filters is shown in Figure 5B. In particular, ET-1
induced a migratory pattern characterized by a huge recruit-
ment of cell populations that maintained close connections
with one another, which was blunted only by B-BQ788. We
also tested the migratory activity of ET-1 in two other cell
lines, GN11 and SH-SY-5Y. The immortalized GN11 cells,
intrinsically motile like GnRH cells, provided an excellent
cellular model of migrating GnRH neurons that are arrested
during their transit to the brain. The human neuroblastoma
SH-SY-5Y cell line, a clonal derivative from primary tumors
of neural crest cells, represented a validmodel of the invasive
behavior of neural crest cells. Even in these cell lines ET-1
(107 and 108 m) induced a strictly ETB-dependent migra-
tory pattern. In fact, in both GN11 (n 4) and SH-SY5Y (n
3) cells, ET-1 induced a significant (P 0.0005) increase in cell
migration, which was completely abolished by B-BQ788 but
not by A-BQ123 (Fig. 6, A and B).
Crosstalk of ET-1 and GnRH peptides in FNC-B4 neurons
The aforementioned results, taken together, strongly sug-
gest that ET-1 induced migration in neural cells and, in par-
ticular, in GnRH-producing cells, through ETB receptors.
Previous studies have demonstrated that FNC-B4 cells pro-
duce and respond to ET-1; this peptide not only positively
regulatesGnRH secretion (acting through the ETA receptors)
but also stimulates proliferation (acting through ETB recep-
tors) (12). GnRH induced in the same cells GnRH release and
a clear migratory pattern (27). Now we observed GnRH-
induced ET-1 production that is able to elicit FNC-B4 cell
migration. The aim of this study was also to investigate
whether migration and release due to GnRH were, at least
partially, mediated by a GnRH-induced activation of ET-1
signaling. We found that, in FNC-B4 cells, increasing con-
centrations (1012 to 106 m) of buserelin, a GnRH agonist,
induced a 9-fold increase in ET-1 release (EC50 of 0.95 0.17
nm; n 3) (Fig. 7). To test whether an ET-1-driven autocrine
loop was involved in GnRH-induced GnRH secretion, we
performed GnRH release experiments in the presence of
selective receptor antagonists. As reported previously (12,
27), both buserelin and ET-1 (107 m) stimulated GnRH se-
cretion (Fig. 8), which was only abolished by their cognate
antagonists. In fact, neither the ET-1 antagonists A-BQ123/
B-BQ788 nor cetrorelix affected GnRH secretion induced by
buserelin andET-1, respectively. Interestingly, onlyA-BQ123
blunted the stimulatory effect of ET-1, thus confirming the
involvement of ETA receptors in GnRH secretion (n  4; *,
P 0.0005 vs. control value 100%) (12). The specific GnRH
antagonist cetrorelix (107m) bluntedGnRH-induced release
in the presence of buserelin, although it did not modify
FIG. 5. Biological effects of ETB receptor activation in FNC-B4neurons. A, Cellmigration of FNC-B4 cells towardET-1was performed according
to Materials and Methods. Increasing concentrations of ET-1, with BQ123 or BQ788 (107 M), were added to the bottom chambers. Effect of
IRL-1620 is also shown. FNC-B4 cells responded to SFM conditions, showing spontaneous random migration [7  1.4 cells per HPF after 6 h
of incubation; n  30]. ET-1 induced a 4- to 6-fold increase in migratory pattern in FNC-B4 cells, in a dose-dependent manner (from 109 to
107 M; *, P  0.0005 vs. control conditions, SFM). IRL-1620 (107 M) induced a similar increase to an equimolar concentration of ET-1 (*, P 
0.0005 vs. control). BQ788 counteracted ET-1 effects, whereas BQ123 did not reduce ET-1-induced migration (*, P  0.0005; n  12). B, A
representative pattern of migrating cells on Boyden chamber filters, under different experimental conditions, is shown. Scale bar, 0.03 m.
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GnRH release in the presence of ET-1 (n  4; *, P  0.0005
vs. control value  100%). Similar results were obtained
through cell migration. As shown in Fig 9, we observed a
higher degree of migratory potency of the ET-1 peptide with
respect to the GnRH peptide (a 4- to 6-fold increase with
respect to a 3- to 4-fold increase; n 6; *,P 0.0005 vs. control
conditions). Similar results were observed after stimulation
of cells with the GnRH analog buserelin (data not shown).
Furthermore, we observed that the ETA receptor antagonist
A-BQ123 was ineffective in the presence of either ET-1 (107
m) (n  6; *, P  0.0005 vs. control) or GnRH (at the same
concentration) (n  6; *, P  0.0005 vs. control) stimulation.
However, ETB receptor antagonist B-BQ788, effective in
counteracting ET-1migration (n 6; *, P values were ns), did
not significantly blunt theGnRH-inducedmigrating capacity
(n 6; *, P 0.0005 vs. control). Cetrorelix was able to blunt
GnRH migration (n  6; *, P value was ns), although it was
ineffective in blunting ET-1-induced migration (n 6; *, P
0.0005 vs. control) (Fig. 9).
Discussion
This study is the first to document that human olfactory
GnRH-secreting neuroblasts, FNC-B4 cells, are able to mi-
grate in response to ET-1. This ability to migrate was ob-
served also in the immortalized mouse GnRH-expressing
neuronal cell line GN11. A striking feature of this report is
that ET-1 migration was elicited by selective ETB receptor
recruitment and was completely independent of the previ-
ously reported ETA-induced GnRH secretion (12). Primary
human GnRH-secreting neuroblasts FNC-B4, established
from fetal olfactory epithelium, and immortalized GnRH-
expressing neuronal cell line GN11, isolated from an olfac-
tory tumor of migration-arrested GnRH neurons, retain
properties found in vivo in either the early or the later stages
of GnRH neuronal navigation (27, 29, 31, 41, 42). Thus, these
cell lines represent excellent models to study prenatal GnRH
neurons. The results herein presented show that ET-1 re-
cruitment is due to ETB receptor activation. By using ETB
receptor antagonist B-BQ788, a significant inhibition of ET-
1-inducedmigrationwas observed. FNC-B4 cells present two
different binding receptors, i.e. the ETA and ETB receptors.
These two classes of molecules are involved in different
biological responses. ETA receptor recruitment induced
GnRH secretion,whereas ETB receptor stimulatedDNA syn-
thesis (12). In this report, we show that ET-1, through ETB
receptor recruitment, was able to trigger a striking morpho-
logical activation of cells toward a clear migratory pattern
and intracellular calcium increase. ET-1 induced modifica-
tions in cell shape and development of cytoplasmic protru-
sions and lamellipodia extensions, associated with actin pro-
tein expression. This recruitment led to the formation of a
huge intercellular network, which probably constituted the
morphological basis of cell activation and the consequent
induction of multiple intercellular crosstalks (3).
Previous researches has demonstrated that FNC-B4 cells
FIG. 6. Migration of GN11 or SH-SY5Y cells toward ET-1. Effect of
ET-1 (108 and 107 M), with or without BQ123 or BQ788 (107 M),
on cell migration of GN11 (A) or SH-SY5Y (B), performed according
to Materials and Methods. ET-1 at all the concentration tested in-
duced in both GN11 cells and in the human neuroblastoma SH-SY5Y
cells a significant (*, P 0.0005) increase in migratory pattern. ET-1
(107 M)-induced cell migration was completely counteracted by an
equimolar concentration of BQ788 but not of BQ123 (*, P 0.0005 vs.
control).
FIG. 7. Crosstalk of ET-1 and GnRH peptides in FNC-B4 neurons.
Effects of GnRH on ET-1 production in FNC-B4 neurons. RIA of ET-1
in conditionedmedia fromFNC-B4 cells. In the presence of increasing
concentrations of buserelin (from 1012 to 106 M), a dose-dependent
9-fold increase in ET-1 secretion (EC50 of 0.95  0.17 nM; n  3) was
observed.
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express ET-1 and respond to ET-1 through a GnRH release,
which, in turn, was able to induce FNC-B4 cells to migrate
(12, 27). Here, we demonstrate that GnRH stimulated ET-1
release. Because ET-1 stimulated motility and GnRH release,
we investigated whether these GnRH-related effects may be,
at least partially, mediated by a GnRH-induced activation of
ET-1 signaling. Our findings suggest a crosstalk between
these two neuropeptides. In fact, functional data, by using
selective antagonists, indicate that FNC-B4 cells were inde-
pendently and selectively stimulated by the two different
peptides. Thus, ET-1, through ETA/ETB and GnRH receptor
crosstalk, may participate in differentiation of the neuroen-
docrine phenotype of FNC-B4 olfactory neuroblasts.
In the olfactory epithelium, proliferation of neural pre-
cursor cells anddifferentiation of their progeny into olfactory
receptor neurons begin during embryogenesis and continue
throughout life (43, 44). The ET-3/ETB pathway has the
potential to differentiate neural crest cells to multipotent
precursors (45–47). Thus, exposure of FNC-B4 neuroblasts to
ET-1 may lead to different stages of differentiation of func-
tional activation. The first one is characterized by an imma-
ture and undifferentiated stage, with a huge proliferative
commitment, and the second one, more differentiated, is
characterized by morphological and cytoskeletal activation,
the acquisition of clear chemotactic properties, and the re-
cruitment of both subtypes of ET andGnRH receptors. These
receptors, together with functional recruitment of both
GnRH and ET-1 molecules, are able to crosstalk and interact
with each other (the so-called “loop activity between ET and
GnRH”). We suggest that the onset of this activity loop plays
FIG. 9. Effects of ET-1 and GnRH agonists and antag-
onists on FNC-B4 migration. ET-1 or GnRH (107 M),
with or without BQ123, BQ788, or cetrorelix (107 M),
were added to the bottom chambers. ET-1 and GnRH
elicited a sustained increase in migration (both *, P 
0.0005 vs. control). ET-1 effect was completely blocked
by BQ788 but not by BQ123 and cetrorelix (both *, P 
0.0005 vs. control). GnRH-induced migration was com-
pletely counteracted by cetrorelix but not by the two
ET-1 antagonists (both *, P  0.0005 vs. control). Ex-
periments were performed in triplicate. CTL, Control.
FIG. 8. Effects of ET-1 and GnRH ago-
nists and antagonists on GnRH release
from FNC-B4 cells. ET-1 (107 M) and
buserelin (107 M) induced 3-fold and
4-fold increase, respectively, in GnRH
secretion (both *, P  0.0005 vs. con-
trol). ET-1 stimulation on GnRH re-
lease was unaffected by BQ788 (107 M;
*, P  0.0005 vs. control) and cetrorelix
(107 M; *, P  0.0005 vs. control) but
almost completely blunted by BQ123
(107 M). Buserelin stimulation was un-
affected by both ET-1 antagonists (both
*,P 0.0005 vs. control) but completely
abrogated by cetrorelix. Columns indi-
cate the percentage of increase inGnRH
secretion over the control value (100%),
as measured by RIA. Experiments were
done in triplicate. CTL, Control.
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a role underlying the development of the specialized neu-
roendocrine cells as they migrate through nasal regions.
Maggi et al. (12) have shown that, during early embryonic
life, ET-1 gene and protein, as well as endothelin-converting
enzyme-1, are present in cells in the olfactory epithelium.
From these data, together with our in vitro data, we speculate
that, in the in vivo situation, ET-1 interacts with growth and
differentiating factors not only to maintain a reservoir of
GnRH-secreting neural cells but also to stimulate cell mi-
gration and a fully activated phenotype. Therefore, ET-1
could play a role in both guiding GnRH-secreting human
neurons during their migration and orchestrating their sub-
sequent differentiation.
During early embryogenesis, brain areas that undergo
rapid neurogenic development and migration of cells
through a differentiatingmatrix require very high energy for
nutrients and the disposal of waste products. These require-
ments are best met by a rich blood supply. These needs
constitute a possible trigger for the development of an elab-
orate “cellulo-vascular bridge” from the placode epithelium
across the nasal septum and into the ventromedial forebrain
(48). A close association between these angiogenic mecha-
nisms and migration of GnRH neurons has been reported in
embryonic mice, in early stage human embryos, and in those
fetuses affected by Kallmann’s syndrome (48). Angiogenesis
is an important early event not only in normal development
but also in tumor progression, beginning in premalignant
lesions (49). The endothelin system represents one of the
most studied growth factor families that has been involved
in modulating angiogenesis (50). Moreover, a close associ-
ation between the loss of ETB receptormRNAexpression and
the onset of a metastatic phenotype of neuroblastoma tu-
mors, strictly associated with the disease progression, has
been described previously (51). The blunted migration ob-
served through specific ETB receptor antagonism in a hu-
man-derived neuroblastoma cell line suggested the possible
role of ETB receptor activation in neoplastic differentiation.
We thus hypothesize that ETB receptor signaling may be
required in in vivo conditions to maintain a mature neuronal
differentiation. Additional studies are needed to clarify
whether the loss of ETB receptor expression during devel-
opment can represent one of the underlyingmolecularmech-
anisms for both the hypogonadotropic hypogonadism as
well as the onset of olfactory-derived tumors.
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